title: Population structure of recrudescent Plasmodium falciparum isolates from western Uganda.
abstract: It has been proposed that polymorphisms of the Merozoite Surface Protein 1 and 2 (MSP1 and MSP2) and the Glutamate Rich Protein (GLURP) genes can be considered as genetic markers for the genotyping of field populations of Plasmodium falciparum. During a field study on in vivo drug resistance against chloroquine, sulphadoxine/pyrimethamine (S/P) and cotrimoxazole in West Uganda, sensitive and resistant isolates were collected from patients by fingerprick for genotyping. 59 (72.8%) of the 81 P. falciparum samples isolated at day 0 showed multiclonal infection with 2-7 clones. Among the isolates we investigated, presence of the allelic family MAD20 of MSP1 at day 0 was significantly (P = 0.0041) associated with decreased resistance to antimalarials. Use of this method in a field study on in vivo drug resistance demonstrates another potential application of genotyping as a tool for epidemiological investigations.
authors.affiliation: Department of Infectious Diseases and Tropical Medicine, University of Munich, Germany. jelinek@lrz.uni-muenchen.de
authors.forename: T
authors.initials: T
authors.lastname: Jelinek
authors.forename: A H
authors.initials: AH
authors.lastname: Kilian
authors.forename: A
authors.initials: A
authors.lastname: Westermeier
authors.forename: S
authors.initials: S
authors.lastname: Pröll
authors.forename: G
authors.initials: G
authors.lastname: Kabagambe
authors.forename: H D
authors.initials: HD
authors.lastname: Nothdurft
authors.forename: F
authors.initials: F
authors.lastname: von Sonnenburg
authors.forename: T
authors.initials: T
authors.lastname: Löscher
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000953:Antigens, Protozoan / Q000235:genetics; D000962:Antimalarials / Q000494:pharmacology* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002738:Chloroquine / Q000494:pharmacology / Q000627:therapeutic use; D004338:Drug Combinations; D004351:Drug Resistance / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D007223:Infant; D016778:Malaria, Falciparum / Q000188:drug therapy / Q000453:epidemiology / Q000469:parasitology*; D008297:Male; D020066:Merozoite Surface Protein 1 / Q000235:genetics; D008875:Middle Aged; D018512:Parasitemia / Q000469:parasitology; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000235:genetics* / Q000302:isolation & purification; D015800:Protozoan Proteins / Q000235:genetics; D011739:Pyrimethamine / Q000494:pharmacology / Q000627:therapeutic use; D013413:Sulfadoxine / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000494:pharmacology / Q000627:therapeutic use; D014454:Uganda / Q000453:epidemiology
chemical_list: D000953:Antigens, Protozoan; D000962:Antimalarials; D004338:Drug Combinations; D020066:Merozoite Surface Protein 1; D015800:Protozoan Proteins; C065974:merozoite surface protein 2, Plasmodium; C072492:glutamate-rich protein, Plasmodium; C001205:fanasil, pyrimethamine drug combination; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D013413:Sulfadoxine; D002738:Chloroquine; D011739:Pyrimethamine